Cite
Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma
MLA
Yongkang Xu, et al. “Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Programmed Cell Death Protein-1 Antibody and Lenvatinib for Advanced Hepatocellular Carcinoma.” Frontiers in Medicine, vol. 9, Sept. 2022. EBSCOhost, https://doi.org/10.3389/fmed.2022.919069.
APA
Yongkang Xu, Shumin Fu, Ye Mao, Shenglan Huang, Dan Li, & Jianbing Wu. (2022). Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma. Frontiers in Medicine, 9. https://doi.org/10.3389/fmed.2022.919069
Chicago
Yongkang Xu, Shumin Fu, Ye Mao, Shenglan Huang, Dan Li, and Jianbing Wu. 2022. “Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined with Programmed Cell Death Protein-1 Antibody and Lenvatinib for Advanced Hepatocellular Carcinoma.” Frontiers in Medicine 9 (September). doi:10.3389/fmed.2022.919069.